RAHUL NAVIN MEDIWALA
Prescription History 1003854597
Internal Medicine - Nephrology in Reno, NV
NPI Status: Active since June 04, 2006
Contact Information
1500 E 2ND ST
SUITE 201
RENO, NV
ZIP 89502
Phone: (775) 982-3355
Fax: (775) 982-3356
Prescription History for Informed Healthcare Decisions
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for RAHUL NAVIN MEDIWALA, an active Nephrology specialist practicing in Reno, NV. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 300 documented patient claims. Among these therapy options, the most frequently utilized medication is Shingrix, which accounts for 121 claims alone.
Abrysvo
Generic Formulation: Rsv Vacc, Pref A And Pref B/PfSpecialty: NephrologyProvider Avg Cost Per Claim
$294.25
State Avg Cost Per Claim
--
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
Adacel Tdap
Generic Formulation: Diph,pertuss(Acell),tet Vac/PfSpecialty: NephrologyProvider Avg Cost Per Claim
$50.73
State Avg Cost Per Claim
$65.32
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
This vaccine is used to keep up protection (immunity) against diphtheria, tetanus (lockjaw) and pertussis (whooping cough) in children and adults who have been vaccinated for these diseases in the past. It may also be given during the third trimester of pregnancy to help prevent pertussis in the newborn baby. Vaccination is the best way to protect against these life-threatening diseases. Vaccines work by causing the body to produce its own protection (antibodies). Booster doses are needed to keep up immunity because antibody levels may become too low over time to provide the needed protection.
Arexvy
Generic Formulation: Rsvpref3 Antigen/As01e/PfSpecialty: NephrologyProvider Avg Cost Per Claim
$282.89
State Avg Cost Per Claim
--
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
Shingrix
Generic Formulation: Varicella-Zoster Ge/As01b/PfSpecialty: NephrologyProvider Avg Cost Per Claim
$180.84
State Avg Cost Per Claim
$195.96
Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.
Dataset Methodology & CMS Source Information
This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like RAHUL NAVIN MEDIWALA provides transparency into local medical care patterns within Reno, NV.
Key Learning Objectives for this Profile:
- Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
- Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Nephrology** practice concentrations.
- Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
- Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.
Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.
